Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis; and two Phase 2 clinical trials in the United States for the treatment of patients with motor neuron disease in amyotrophic lateral sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT product online through its e-commerce Website, as well as through specialty retailers. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLKS
CUSIPN/A
Phone617-874-1821
Debt
Debt-to-Equity RatioN/A
Current Ratio4.46
Quick Ratio4.39
Price-To-Earnings
Trailing P/E Ratio-0.22
Forward P/E Ratio-0.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.27 million
Price / Sales6.17
Cash FlowN/A
Price / CashN/A
Book Value$1.62 per share
Price / Book0.27
Profitability
EPS (Most Recent Fiscal Year)($1.99)
Net Income$-34,430,000.00
Net Margins-3,092.50%
Return on Equity-137.76%
Return on Assets-116.00%
Miscellaneous
Employees22
Outstanding Shares18,070,000
Market Cap$8.41 million
Flex Pharma (NASDAQ:FLKS) Frequently Asked Questions
What is Flex Pharma's stock symbol?
Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."
How were Flex Pharma's earnings last quarter?
Flex Pharma Inc (NASDAQ:FLKS) issued its quarterly earnings data on Friday, August, 3rd. The biotechnology company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.05. The biotechnology company earned $0.25 million during the quarter, compared to analysts' expectations of $0.20 million. Flex Pharma had a negative return on equity of 137.76% and a negative net margin of 3,092.50%. View Flex Pharma's Earnings History.
When is Flex Pharma's next earnings date?
What price target have analysts set for FLKS?
5 equities research analysts have issued 1-year target prices for Flex Pharma's shares. Their forecasts range from $6.00 to $40.00. On average, they expect Flex Pharma's stock price to reach $17.50 in the next year. This suggests a possible upside of 4,096.6% from the stock's current price. View Analyst Price Targets for Flex Pharma.
What is the consensus analysts' recommendation for Flex Pharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flex Pharma in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Flex Pharma.
What are Wall Street analysts saying about Flex Pharma stock?
Here are some recent quotes from research analysts about Flex Pharma stock:
- 1. According to Zacks Investment Research, "Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts. " (9/5/2018)
- 2. Cantor Fitzgerald analysts commented, "Exploratory Phase II study of FLX-787 in MS showed statistically significant reduction of 27.3% (p=0.001) in frequency of cramps and a 1.4-day increase in the number of cramp-free days (p=0.0457)." (3/27/2018)
Who are some of Flex Pharma's key competitors?
Some companies that are related to Flex Pharma include Lipocine (LPCN), SUMMIT THERAPEU/S (SMMT), Gemphire Therapeutics (GEMP), KITOV PHARMA LT/S (KTOV), vTv Therapeutics (VTVT), BENITEC BIOPHAR/S (BNTC), Jaguar Health (JAGX), Provectus Biopharmaceuticals (PVCT), AEterna Zentaris (AEZS), Akari Therapeutics (AKTX), Innovus Pharmaceuticals (INNV), Edge Therapeutics (EDGE), Soligenix (SNGX), NeuroVive Pharmaceutical (NEVPF) and Sernova (SEOVF).
Who are Flex Pharma's key executives?
Flex Pharma's management team includes the folowing people:
- Dr. William K. McVicar, Pres, CEO & Director (Age 60)
- Dr. Roderick MacKinnon, Co-Founder & Co-Chair of Scientific Advisory Board (Age 62)
- Mr. John McCabe, CFO, Treasurer & Sec. (Age 48)
- Mr. Robert Hadfield, Advisor (Age 40)
- Dr. Thomas C. Wessel, Outside Advisor (Age 62)
When did Flex Pharma IPO?
(FLKS) raised $60 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.
Has Flex Pharma been receiving favorable news coverage?
News stories about FLKS stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Flex Pharma earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Flex Pharma.
Who are Flex Pharma's major shareholders?
Flex Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.31%). Company insiders that own Flex Pharma stock include Christoph H Westphal and John P Mccabe. View Institutional Ownership Trends for Flex Pharma.
Which institutional investors are buying Flex Pharma stock?
FLKS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Flex Pharma stock in the last two years include Christoph H Westphal and John P Mccabe. View Insider Buying and Selling for Flex Pharma.
How do I buy shares of Flex Pharma?
Shares of FLKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flex Pharma's stock price today?
One share of FLKS stock can currently be purchased for approximately $0.4170.
How big of a company is Flex Pharma?
Flex Pharma has a market capitalization of $8.41 million and generates $1.27 million in revenue each year. The biotechnology company earns $-34,430,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Flex Pharma employs 22 workers across the globe.
How can I contact Flex Pharma?
Flex Pharma's mailing address is 800 Boylston Street 24thFloor, Boston MA, 02199. The biotechnology company can be reached via phone at 617-874-1821 or via email at [email protected]
MarketBeat Community Rating for Flex Pharma (NASDAQ FLKS)
MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe FLKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
